BeiGene, a China-based oncology company, has announced the opening of its flagship US facility in Hopewell, New Jersey, at the Princeton West Innovation Campus. The new facility features state-of-the-art biologics manufacturing capabilities and a clinical research and development centre that reinforces the company's distinctive model as an innovator in oncology.

With more than 30 molecules in clinical or commercial stage, the 42-acre facility provides the flexibility to scale up production of its innovative medicines today and in the future, meeting the needs of cancer patients.

BeiGene's $800 million investment is the result of a three-year project to expand the company's integrated presence in manufacturing and research and development in the US. BeiGene will create hundreds of highly specialised jobs in the area by the end of 2025.

New Jersey is a global leader in biopharmaceutical manufacturing and R&D, with nine of the world's top 10 R&D companies present in the state. New Jersey has one of the largest biopharmaceutical manufacturing workforces in the country, and its infrastructure and connectivity ensure access to major markets around the world.

The site features approximately 400,000 square feet of capacity dedicated to commercial-stage biologics manufacturing, with room for future expansion, allowing flexibility as BeiGene's pipeline continues to develop. The facility complements BeiGene's late-stage clinical research and development capabilities, which have driven the company's rapid rise to global leadership in the oncology industry. The new facility extends BeiGene's existing capabilities, enabling the company to produce at scale, reducing costs, ensuring supply chain resilience, avoiding global disruptions, protecting capacity, and adapting quickly to the latest innovative modalities.